Tohoku University Technology: Prognostic Biomarker for Cancer Patients: T20-3069
The expression level of LILRB4 can accurately predict the prognosis of cancer patients.
The immunosuppressive receptor LILRB4 (B4) is one of the immune checkpoint (CP) molecules that has garnered attention in cancer treatment, particularly represented by PD-1, but its true ligand has remained unknown. In the prior application of the inventors (related literature 1), a novel immune CP inhibitor and a therapeutic agent containing it were provided based on the discovery of the physiological ligand fibronectin (FN) for B4 and the finding that immune regulation is possible by inhibiting B4-FN binding. In this invention, a monoclonal antibody that inhibits FN binding to B4 was uniquely produced, and the prognostic prediction of lung cancer patients using B4 as a biomarker was validated. Specifically, by early identification of poor prognosis groups, it is possible to support appropriate choices such as treatment with immune checkpoint inhibitors.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
